Trial reportStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2014
Hypofractionation with simultaneous integrated boost for early breast cancer: results of the German multicenter phase II trial (ARO-2010-01).
Trial report in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.Breast (Edinburgh, Scotland) · 2022Trial
- A Phase II Trial of Once Weekly Hypofractionated Breast Irradiation for Early Stage Breast Cancer.Annals of surgical oncology · 2021Trial
- Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Trial
- Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Trial
- Accelerated partial breast irradiation with external beam radiotherapy : First results of the German phase 2 trial.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2017Trial
- Short-Course Hypofractionated Radiation Therapy With Boost in Women With Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.International journal of radiation oncology, biology, physics · 2016Trial
- Ultra-hypofractionated 5-fraction radiation therapy for early breast cancer into whole breast and regional nodes: experience in a tertiary hospital.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Observational
- Comparison of simultaneous integrated tumor bed boost and sequential boost during hypofractionated whole-breast irradiation after breast-conserving surgery.Clinical and translational radiation oncology · 2025Article
- Comparison of helical and TomoDirect techniques with simultaneous integrated boost in early breast cancer patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Article
- Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates.Radiation oncology journal · 2022Article
- Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: A systematic literature review.Translational oncology · 2022Review
- Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy.Physics and imaging in radiation oncology · 2022Article
- Accelerated hypofractionated breast radiotherapy with simultaneous integrated boost: a feasibility study.Radiation oncology journal · 2022Article
- Long-term oncological outcomes of hypofractionated versus conventional fractionated whole breast irradiation with simultaneous integrated boost in early-stage breast cancer.Radiation oncology journal · 2022Article
- Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Long-term results of hypofractionation with concomitant boost in patients with early breast cancer: A prospective study.PloS one · 2021Article
- Hybrid planning techniques for hypofractionated whole-breast irradiation using flattening filter-free beams.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Recent advances in radiotherapy of breast cancer.Radiation oncology (London, England) · 2020Review
- Altered fractionation in radiation therapy for breast cancer in the elderly: are we moving forward?Translational cancer research · 2020Review
- Adjuvant whole breast radiotherapy with simultaneous integrated boost to tumor bed with intensity modulated radiotherapy technique in elderly breast cancer patients.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility of hypofractionation with SIB in all settings in Germany to prepare a multicenter treatment comparison.
methodsEligible patients had histopathologically confirmed breast cancer operated by BCS. Patients received WBI 40.0 Gy in 16 fractions of 2.5 Gy. A SIB with 0.5 Gy per fraction was administered to the tumor bed, thereby giving 48.0 Gy in 16 fractions to the boost-PTV sparing heart, LAD, lung, contralateral breast. The primary study objective was feasibility, administration of specified dose in 16 fractions within 22-29 days with adherence to certain dose constraints (heart; LAD; contralateral breast); secondary endpoints were toxicity, QoL.
results151 patients were recruited from 7 institutions between 07/11-10/12. 10 patients met exclusion criteria prior to irradiation. All but two patients (99%) received the prescribed dose in the PTVs. Adherence to dose constraints and time limits was achieved in 89% (95% CI 82% to 93%). 11 AE were reported in 10 patients; five related to concurrent endocrine therapy. Two of the AEs were related to radiotherapy: grade 3 hot flushes in two cases. QoL remained unchanged.
conclusionHypofractionation with a SIB is feasible and was well tolerated in this study.
Indexed as
Identifiers
24737540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.